Acamprosate UK Application Filed
Lipha Pharmaceuticals has submitted a license application for its gamma-aminobutyric acid agonist Campral (acamprosate) in the UK for the long-term maintenance of alcohol abstinence in alcohol-dependent patients.
The company says that the drug has been tested in trials in 12 European countries, including the UK. The drug was given at a dose of 2g/day for between six and 12 months. Treated patients experienced a two-fold increase in rehabilitation rates compared to those who had undergone detoxification and had received psychotherapy or had taken hypnotics.
The patients most suited to this kind of treatment seem to be those who are well motivated to give up alcohol and for whom acamprosate could be integrated into a comprehensive treatment program with other available supportive measures.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze